Evidence map›Paper›PMID 37128226›Full record

ArticleGlobal health & medicine2023

Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions: A retrospective observational study.

Yusuke Miyazato, Shinya Tsuzuki, Akihiro Matsunaga, Shinichiro Morioka, Mari Terada, Sho Saito, Noriko Iwamoto, Satoshi Kutsuna, Yukihito Ishizaka, Norio Ohmagari

Open access · bronzeAbstract read
In one paragraph

Article in Global health & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yusuke MiyazatoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinya TsuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiro MatsunagaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Shinichiro MoriokaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mari TeradaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KutsunaDepartment of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yukihito IshizakaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPOsaka University · JPUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symptoms that persist after an acute coronavirus disease 2019 (COVID-19) are referred to as post- COVID conditions. Although the cause of post-COVID conditions remains unclear, the host immune response to SARS-CoV-2 may be involved. Hence, we aimed to investigate the effect of serum antibody titers against SARS-CoV-2 on the development of post-COVID conditions. We conducted a retrospective observational study of COVID-19-recovered individuals who attended the clinic at the National Center for Global Health and Medicine between January 2020 and April 2021. Serum SARS-CoV-2 anti-spike antibody titers were measured and a questionnaire survey was used to collect information on the presence of post-COVID conditions and demographic characteristics of the participants. Participants were then divided into two groups: high peak antibody titer group [≥ 0.759 OD450 value], and low peak antibody titer group [< 0.759 OD450 value] and compared their frequency of post-COVID conditions. Of 526 individuals attending the clinic, 457 (86.9%) responded to the questionnaire. We analyzed the data of 227 (49.7%) participants with measurements of serum antibody titers during the peak period. The incidence of depressed mood was significantly higher in the group with higher antibody titers (odds ratio: 2.34, 95% CI: 1.17-4.67,

Indexed as

antibody titerCOVID-19post-COVID conditionquestionnaire surveySARS-CoV-2

Identifiers

PMID37128226
PMCPMC10130543
OpenAlexW4365128652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.